Literature DB >> 32016017

Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?

Daniele Focosi1, Marco Tuccori2, Fabrizio Maggi3.   

Abstract

Year:  2019        PMID: 32016017      PMCID: PMC6976515          DOI: 10.21037/atm.2019.11.07

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  25 in total

1.  Can Immune Checkpoint Inhibitors Keep JC Virus in Check?

Authors:  Igor J Koralnik
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

2.  Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

Authors:  Sandra Vukusic; Fabien Rollot; Romain Casey; Julie Pique; Romain Marignier; Guillaume Mathey; Gilles Edan; David Brassat; Aurélie Ruet; Jérôme De Sèze; Elisabeth Maillart; Hélène Zéphir; Pierre Labauge; Nathalie Derache; Christine Lebrun-Frenay; Thibault Moreau; Sandrine Wiertlewski; Eric Berger; Xavier Moisset; Audrey Rico-Lamy; Bruno Stankoff; Caroline Bensa; Eric Thouvenot; Olivier Heinzlef; Abdullatif Al-Khedr; Bertrand Bourre; Mathieu Vaillant; Philippe Cabre; Alexis Montcuquet; Abir Wahab; Jean-Philippe Camdessanché; Ayman Tourbah; Anne-Marie Guennoc; Karolina Hankiewicz; Ivania Patry; Chantal Nifle; Nicolas Maubeuge; Céline Labeyrie; Patrick Vermersch; David-Axel Laplaud
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

Review 3.  Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?

Authors:  Pauline De Bruyn; Dirk Van Gestel; Piet Ost; Vibeke Kruse; Lieve Brochez; Hans Van Vlierberghe; Arnaud Devresse; Véronique Del Marmol; Alain Le Moine; Sandrine Aspeslagh
Journal:  Curr Opin Oncol       Date:  2019-03       Impact factor: 3.645

4.  Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.

Authors:  Sarah Gheuens; Evelyn Bord; Santosh Kesari; David M Simpson; Rajesh T Gandhi; David B Clifford; Joseph R Berger; Long Ngo; Igor J Koralnik
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

5.  SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.

Authors:  Jens M Chemnitz; Richard V Parry; Kim E Nichols; Carl H June; James L Riley
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

6.  Treatment of progressive multifocal leukoencephalopathy with interleukin 7.

Authors:  Karl B Alstadhaug; Thérèse Croughs; Stian Henriksen; Céline Leboeuf; Irini Sereti; Hans H Hirsch; Christine Hanssen Rinaldo
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

7.  Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era.

Authors:  J L Casado; I Corral; J García; J Martinez-San Millán; E Navas; A Moreno; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-16       Impact factor: 3.267

Review 8.  Immune checkpoint inhibitors in the treatment of virus-associated cancers.

Authors:  Peipei Gao; Cordelle Lazare; Canhui Cao; Yifan Meng; Ping Wu; Wenhua Zhi; Shitong Lin; Juncheng Wei; Xiaoyuan Huang; Ling Xi; Gang Chen; Junbo Hu; Ding Ma; Peng Wu
Journal:  J Hematol Oncol       Date:  2019-06-10       Impact factor: 17.388

9.  Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.

Authors:  Martin Martinot; Guido Ahle; Inesa Petrosyan; Camille Martinez; Dragos M Gorun; Mahsa Mohseni-Zadeh; Samira Fafi-Kremer; Martine Tebacher-Alt
Journal:  Emerg Infect Dis       Date:  2018-08       Impact factor: 6.883

Review 10.  Novel Delivery Systems for Checkpoint Inhibitors.

Authors:  Purushottam Lamichhane; Rahul Deshmukh; Julie A Brown; Silvia Jakubski; Priyanka Parajuli; Todd Nolan; Dewan Raja; Mary Badawy; Thomas Yoon; Mark Zmiyiwsky; Narottam Lamichhane
Journal:  Medicines (Basel)       Date:  2019-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.